Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Coherent to engage in discussions with II-VI following acquisition proposal » 05:07
02/16/21
02/16
05:07
02/16/21
05:07
COHR

Coherent

$257.89 /

+31.66 (+13.99%)

, IIVI

II-VI

$89.82 /

-9.81 (-9.85%)

, MKSI

MKS Instruments

$167.45 /

+5.23 (+3.22%)

, LITE

Lumentum

$94.00 /

+1.41 (+1.52%)

Coherent (COHR) announced…

Coherent (COHR) announced that its board of directors has determined to engage in discussions with II-VI (IIVI) in response to its unsolicited proposal to acquire Coherent in a transaction where each share of Coherent common stock would be exchanged for $130.00 in cash and 1.3055 shares of II-VI common stock. On February 8, Coherent announced that it had received an unsolicited proposal from MKS Instruments (MKSI) to acquire Coherent in a transaction where each share of Coherent common stock would be exchanged for $115.00 in cash and 0.7473 of a share of MKS common stock. Coherent received the unsolicited acquisition proposals from II-VI and MKS following its announcement on January 19, that it had entered into a merger agreement with Lumentum (LITE) pursuant to which Lumentum agreed to acquire Coherent in a transaction where each share of Coherent common stock would be exchanged for $100.00 in cash and 1.1851 shares of Lumentum common stock. Coherent's pending transaction with Lumentum and the alternative transactions proposed by II-VI and MKS are all subject to customary closing conditions, including receipt of U.S. and foreign antitrust approvals and stockholder approvals. Coherent's board of directors has not determined whether II-VI's acquisition proposal is superior to Coherent's pending Lumentum transaction. After conducting a preliminary analysis of II-VI's proposal, however, Coherent's board of directors has determined that II-VI's proposal could lead to a transaction that is superior to its pending transaction with Lumentum. Accordingly, Coherent has determined to engage in discussions with II-VI to further evaluate the comparative benefits and risks of II-VI's proposed transaction relative to Coherent's pending transaction with Lumentum, including the near and long-term financial opportunities of each transaction, the expected completion timing of each transaction, and the closing risks associated with each transaction. As previously announced, the Coherent board of directors is also currently evaluating the acquisition proposal it received from MKS so it will conduct a thorough review of all three transactions in consultation with its financial and legal advisors before making a final determination. There can be no assurances that Coherent will conclude that the transaction proposed by II-VI or MKS is superior to Coherent's pending transaction with Lumentum, so Coherent investors are encouraged to await a final determination from Coherent's board of directors. Notwithstanding its receipt of competing acquisition proposals from II-VI and MKS and ongoing discussions with both companies, Coherent's board of directors continues to recommend Coherent's merger agreement with Lumentum to its stockholders. Coherent's board of directors is not modifying or withdrawing its recommendation with respect to the Lumentum merger agreement and the Lumentum merger at this time, or proposing to do so, and is not making any recommendation with respect to the competing acquisition proposals it has received from II-VI or MKS at this time.

ShowHide Related Items >><<
MKSI MKS Instruments
$167.45 /

+5.23 (+3.22%)

IIVI II-VI
$89.82 /

-9.81 (-9.85%)

COHR Coherent
$257.89 /

+31.66 (+13.99%)

COHR Coherent
$257.89 /

+31.66 (+13.99%)

02/12/21 Benchmark
Benchmark maintains Buy rating on II-VI after Coherent bid
02/11/21 Benchmark
Coherent downgraded to Hold from Buy at Benchmark
02/08/21 Stifel
Coherent bid may force Lumentum to raise offer, says Stifel
02/08/21 Benchmark
Coherent deal with MKS could face regulators' scrutiny, says Benchmark
IIVI II-VI
$89.82 /

-9.81 (-9.85%)

02/10/21 DA Davidson
II-VI price target raised to $115 from $60 at DA Davidson
02/10/21 Cowen
II-VI price target raised to $124 from $86 at Cowen
02/10/21 Canaccord
II-VI price target raised to $152 from $86 at Canaccord
MKSI MKS Instruments
$167.45 /

+5.23 (+3.22%)

LITE Lumentum
$94.00 /

+1.41 (+1.52%)

MKSI MKS Instruments
$167.45 /

+5.23 (+3.22%)

LITE Lumentum
$94.00 /

+1.41 (+1.52%)

IIVI II-VI
$89.82 /

-9.81 (-9.85%)

COHR Coherent
$257.89 /

+31.66 (+13.99%)

  • 02
    Jul
IIVI II-VI
$89.82 /

-9.81 (-9.85%)

COHR Coherent
$257.89 /

+31.66 (+13.99%)

LITE Lumentum
$94.00 /

+1.41 (+1.52%)

IIVI II-VI
$89.82 /

-9.81 (-9.85%)

COHR Coherent
$257.89 /

+31.66 (+13.99%)

LITE Lumentum
$94.00 /

+1.41 (+1.52%)

On The Fly
Fly Intel: Wall Street's top stories for Friday » 16:15
02/12/21
02/12
16:15
02/12/21
16:15
DIS

Disney

$187.69 /

-3.27 (-1.71%)

, EXPE

Expedia

$146.49 /

-3.13 (-2.09%)

, IIVI

II-VI

$89.82 /

-9.81 (-9.85%)

, COHR

Coherent

$257.89 /

+31.66 (+13.99%)

, LITE

Lumentum

$94.00 /

+1.41 (+1.52%)

, MKSI

MKS Instruments

$167.45 /

+5.23 (+3.22%)

, MRNA

Moderna

$183.60 /

+0.18 (+0.10%)

, PFE

Pfizer

$34.72 /

+0.29 (+0.84%)

, GOOG

Alphabet

$2,104.55 /

+8.99 (+0.43%)

, GOOGL

Alphabet Class A

$2,095.83 /

+6.23 (+0.30%)

, MSFT

Microsoft

$244.99 /

+0.6 (+0.25%)

, QCOM

Qualcomm

$147.98 /

+2.53 (+1.74%)

, NVDA

Nvidia

$598.42 /

-11.89 (-1.95%)

, XERS

Xeris Pharmaceuticals

$6.84 /

+0.22 (+3.32%)

, IMGN

ImmunoGen

$10.51 /

+2.405 (+29.67%)

, HUBS

HubSpot

$501.62 /

+69.38 (+16.05%)

, FOLD

Amicus

$12.56 /

-6.2 (-33.05%)

, LLNW

Limelight Networks

$3.96 /

-0.6 (-13.16%)

, NWL

Newell Brands

$24.19 /

-1.85 (-7.10%)

The major averages closed…

ShowHide Related Items >><<
XERS Xeris Pharmaceuticals
$6.84 /

+0.22 (+3.32%)

QCOM Qualcomm
$147.98 /

+2.53 (+1.74%)

PFE Pfizer
$34.72 /

+0.29 (+0.84%)

NVDA Nvidia
$598.42 /

-11.89 (-1.95%)

MSFT Microsoft
$244.99 /

+0.6 (+0.25%)

MRNA Moderna
$183.60 /

+0.18 (+0.10%)

MKSI MKS Instruments
$167.45 /

+5.23 (+3.22%)

LLNW Limelight Networks
$3.96 /

-0.6 (-13.16%)

LITE Lumentum
$94.00 /

+1.41 (+1.52%)

IMGN ImmunoGen
$10.51 /

+2.405 (+29.67%)

IIVI II-VI
$89.82 /

-9.81 (-9.85%)

HUBS HubSpot
$501.62 /

+69.38 (+16.05%)

GOOG Alphabet
$2,104.55 /

+8.99 (+0.43%)

FOLD Amicus
$12.56 /

-6.2 (-33.05%)

EXPE Expedia
$146.49 /

-3.13 (-2.09%)

DIS Disney
$187.69 /

-3.27 (-1.71%)

COHR Coherent
$257.89 /

+31.66 (+13.99%)

DIS Disney
$187.69 /

-3.27 (-1.71%)

02/12/21 Loop Capital
Disney price target raised to $230 from $190 at Loop Capital
02/12/21 Evercore ISI
Disney price target raised to $210 from $200 at Evercore ISI
02/12/21 JPMorgan
Disney price target raised to $220 from $210 at JPMorgan
02/12/21 Credit Suisse
Disney price target raised to $218 from $192 at Credit Suisse
EXPE Expedia
$146.49 /

-3.13 (-2.09%)

02/12/21 Stifel
Expedia price target raised to $140 from $117 at Stifel
02/12/21 Cowen
Expedia price target raised to $150 from $140 at Cowen
02/12/21 Benchmark
Expedia price target raised to $175 from $120 at Benchmark
02/12/21 Barclays
Expedia price target raised to $167 from $140 at Barclays
IIVI II-VI
$89.82 /

-9.81 (-9.85%)

02/12/21 Benchmark
Benchmark maintains Buy rating on II-VI after Coherent bid
02/10/21 DA Davidson
II-VI price target raised to $115 from $60 at DA Davidson
02/10/21 Cowen
II-VI price target raised to $124 from $86 at Cowen
02/10/21 Canaccord
II-VI price target raised to $152 from $86 at Canaccord
COHR Coherent
$257.89 /

+31.66 (+13.99%)

02/11/21 Benchmark
Coherent downgraded to Hold from Buy at Benchmark
02/08/21 Stifel
Coherent bid may force Lumentum to raise offer, says Stifel
02/08/21 Benchmark
Coherent deal with MKS could face regulators' scrutiny, says Benchmark
LITE Lumentum
$94.00 /

+1.41 (+1.52%)

MKSI MKS Instruments
$167.45 /

+5.23 (+3.22%)

MRNA Moderna
$183.60 /

+0.18 (+0.10%)

02/03/21 Piper Sandler
Moderna's vaccine approved in Singapore, says Piper Sandler
02/01/21
Fly Intel: Top five analyst downgrades
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Oppenheimer
Moderna price target raised to $206 from $178 at Oppenheimer
PFE Pfizer
$34.72 /

+0.29 (+0.84%)

02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
02/03/21 Mizuho
Pfizer price target lowered to $42 from $44 at Mizuho
GOOG Alphabet
$2,104.55 /

+8.99 (+0.43%)

02/12/21 Citi
Citi boosts Alphabet target but shares no longer a top pick
02/08/21 Stephens
Global Payments merchant business advanced by Google pact, says Stephens
02/03/21 JMP Securities
Alphabet price target raised to $2,400 from $1,700 at JMP Securities
02/03/21 JPMorgan
Alphabet price target raised to $2,390 from $2,050 at JPMorgan
GOOGL Alphabet Class A
$2,095.83 /

+6.23 (+0.30%)

MSFT Microsoft
$244.99 /

+0.6 (+0.25%)

02/08/21 KeyBanc
Viva reinforces Microsoft Office/Teams innovation commitment, says KeyBanc
02/08/21 RBC Capital
Datadog price target raised to $110 from $85 at RBC Capital
02/03/21 Wedbush
Cloud arms race hitting another gear with Amazon CEO move, says Wedbush
02/03/21 Jefferies
Alphabet price target raised to $2,400 from $2,150 at Jefferies
QCOM Qualcomm
$147.98 /

+2.53 (+1.74%)

02/10/21 JPMorgan
China mobile shipments data point to 'robust' Apple demand, says JPMorgan
02/08/21 JPMorgan
JPMorgan prefers shares of Qualcomm over Apple
02/04/21
Fly Intel: Top five analyst downgrades
02/04/21
Qualcomm price target raised to $150 from $126 at RBC Capital
NVDA Nvidia
$598.42 /

-11.89 (-1.95%)

02/03/21 New Street
Nvidia upgraded to Neutral from Reduce at New Street
01/26/21 Barclays
Nvidia price target raised to $600 from $550 at Barclays
01/25/21 Citi
Citi moves Marvell up to pick in semiconductor equipment
01/15/21 Truist
Nvidia price target raised to $672 from $643 at Truist
XERS Xeris Pharmaceuticals
$6.84 /

+0.22 (+3.32%)

08/20/20 Mizuho
Mizuho sees no material impact to Xeris following FDA letter about advertising
04/23/20 Mizuho
Xeris Pharmaceuticals price target lowered to $14 from $18 at Mizuho
02/20/20 Mizuho
Xeris Pharmaceuticals price target lowered to $18 from $22 at Mizuho
02/18/20
Fly Intel: Top five analyst initiations
IMGN ImmunoGen
$10.51 /

+2.405 (+29.67%)

12/07/20 Piper Sandler
ImmunoGen price target raised to $6.50 from $5.50 at Piper Sandler
10/26/20 H.C. Wainwright
ImmunoGen assumed with a Buy at H.C. Wainwright
10/19/20 Piper Sandler
Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler
10/05/20 Piper Sandler
Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question'
HUBS HubSpot
$501.62 /

+69.38 (+16.05%)

02/12/21 Needham
HubSpot price target raised to $520 from $400 at Needham
02/12/21 Cowen
HubSpot price target raised to $510 from $400 at Cowen
02/12/21 Raymond James
HubSpot upgraded to Strong Buy from Outperform at Raymond James
02/12/21 Truist
HubSpot price target raised to $600 from $455 at Truist
FOLD Amicus
$12.56 /

-6.2 (-33.05%)

02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 JPMorgan
Amicus downgraded to Neutral on Pompe disease miss at JPMorgan
02/12/21 SVB Leerink
Amicus downgraded to Market Perform from Outperform at SVB Leerink
02/12/21 Cantor Fitzgerald
Amicus downgraded to Neutral from Overweight at Cantor Fitzgerald
LLNW Limelight Networks
$3.96 /

-0.6 (-13.16%)

02/12/21 Lake Street
Limelight Networks price target lowered to $6 from $9 at Lake Street
02/12/21 DA Davidson
Limelight Networks downgraded to Underperform from Neutral at DA Davidson
02/12/21 Raymond James
Limelight Networks downgraded to Market Perform from Outperform at Raymond James
02/12/21 Truist
Limelight Networks downgraded to Hold from Buy at Truist
NWL Newell Brands
$24.19 /

-1.85 (-7.10%)

02/04/21 Deutsche Bank
Newell Brands price target raised to $23 from $18 at Deutsche Bank
01/08/21 BofA
Newell Brands upgraded to Buy on shift away from home at BofA
01/08/21 BofA
Newell Brands upgraded to Buy from Neutral at BofA
01/04/21 Jefferies
Jefferies upgrades 'underappreciated' Newell Brands to Buy from Hold
XERS Xeris Pharmaceuticals
$6.84 /

+0.22 (+3.32%)

QCOM Qualcomm
$147.98 /

+2.53 (+1.74%)

PFE Pfizer
$34.72 /

+0.29 (+0.84%)

NWL Newell Brands
$24.19 /

-1.85 (-7.10%)

NVDA Nvidia
$598.42 /

-11.89 (-1.95%)

MSFT Microsoft
$244.99 /

+0.6 (+0.25%)

MRNA Moderna
$183.60 /

+0.18 (+0.10%)

MKSI MKS Instruments
$167.45 /

+5.23 (+3.22%)

LLNW Limelight Networks
$3.96 /

-0.6 (-13.16%)

LITE Lumentum
$94.00 /

+1.41 (+1.52%)

IMGN ImmunoGen
$10.51 /

+2.405 (+29.67%)

IIVI II-VI
$89.82 /

-9.81 (-9.85%)

HUBS HubSpot
$501.62 /

+69.38 (+16.05%)

GOOGL Alphabet Class A
$2,095.83 /

+6.23 (+0.30%)

GOOG Alphabet
$2,104.55 /

+8.99 (+0.43%)

FOLD Amicus
$12.56 /

-6.2 (-33.05%)

EXPE Expedia
$146.49 /

-3.13 (-2.09%)

DIS Disney
$187.69 /

-3.27 (-1.71%)

COHR Coherent
$257.89 /

+31.66 (+13.99%)

  • 02
    Jul
  • 26
    Jun
  • 19
    May
QCOM Qualcomm
$147.98 /

+2.53 (+1.74%)

PFE Pfizer
$34.72 /

+0.29 (+0.84%)

NVDA Nvidia
$598.42 /

-11.89 (-1.95%)

MSFT Microsoft
$244.99 /

+0.6 (+0.25%)

MRNA Moderna
$183.60 /

+0.18 (+0.10%)

IIVI II-VI
$89.82 /

-9.81 (-9.85%)

HUBS HubSpot
$501.62 /

+69.38 (+16.05%)

GOOG Alphabet
$2,104.55 /

+8.99 (+0.43%)

FOLD Amicus
$12.56 /

-6.2 (-33.05%)

EXPE Expedia
$146.49 /

-3.13 (-2.09%)

DIS Disney
$187.69 /

-3.27 (-1.71%)

COHR Coherent
$257.89 /

+31.66 (+13.99%)

XERS Xeris Pharmaceuticals
$6.84 /

+0.22 (+3.32%)

QCOM Qualcomm
$147.98 /

+2.53 (+1.74%)

PFE Pfizer
$34.72 /

+0.29 (+0.84%)

NWL Newell Brands
$24.19 /

-1.85 (-7.10%)

NVDA Nvidia
$598.42 /

-11.89 (-1.95%)

MSFT Microsoft
$244.99 /

+0.6 (+0.25%)

MRNA Moderna
$183.60 /

+0.18 (+0.10%)

LITE Lumentum
$94.00 /

+1.41 (+1.52%)

IMGN ImmunoGen
$10.51 /

+2.405 (+29.67%)

IIVI II-VI
$89.82 /

-9.81 (-9.85%)

GOOG Alphabet
$2,104.55 /

+8.99 (+0.43%)

FOLD Amicus
$12.56 /

-6.2 (-33.05%)

EXPE Expedia
$146.49 /

-3.13 (-2.09%)

DIS Disney
$187.69 /

-3.27 (-1.71%)

COHR Coherent
$257.89 /

+31.66 (+13.99%)

XERS Xeris Pharmaceuticals
$6.84 /

+0.22 (+3.32%)

QCOM Qualcomm
$147.98 /

+2.53 (+1.74%)

PFE Pfizer
$34.72 /

+0.29 (+0.84%)

NVDA Nvidia
$598.42 /

-11.89 (-1.95%)

MSFT Microsoft
$244.99 /

+0.6 (+0.25%)

MRNA Moderna
$183.60 /

+0.18 (+0.10%)

LLNW Limelight Networks
$3.96 /

-0.6 (-13.16%)

LITE Lumentum
$94.00 /

+1.41 (+1.52%)

GOOGL Alphabet Class A
$2,095.83 /

+6.23 (+0.30%)

GOOG Alphabet
$2,104.55 /

+8.99 (+0.43%)

FOLD Amicus
$12.56 /

-6.2 (-33.05%)

EXPE Expedia
$146.49 /

-3.13 (-2.09%)

DIS Disney
$187.69 /

-3.27 (-1.71%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:09
02/12/21
02/12
12:09
02/12/21
12:09
XERS

Xeris Pharmaceuticals

$7.08 /

+0.46 (+6.95%)

, DIS

Disney

$189.57 /

-1.39 (-0.73%)

, EXPE

Expedia

$146.81 /

-2.81 (-1.88%)

, IIVI

II-VI

$93.24 /

-6.39 (-6.41%)

, COHR

Coherent

$259.58 /

+33.35 (+14.74%)

, LITE

Lumentum

$94.62 /

+2.03 (+2.19%)

, MKSI

MKS Instruments

$167.71 /

+5.49 (+3.38%)

, MRNA

Moderna

$180.40 /

-3.02 (-1.65%)

, PFE

Pfizer

$34.85 /

+0.42 (+1.22%)

, IMGN

ImmunoGen

$10.56 /

+2.455 (+30.29%)

, HUBS

HubSpot

$503.52 /

+71.28 (+16.49%)

, FOLD

Amicus

$12.73 /

-6.03 (-32.14%)

, LLNW

Limelight Networks

$3.58 /

-0.98 (-21.49%)

, NWL

Newell Brands

$24.15 /

-1.89 (-7.26%)

The major averages are…

ShowHide Related Items >><<
XERS Xeris Pharmaceuticals
$7.08 /

+0.46 (+6.95%)

PFE Pfizer
$34.85 /

+0.42 (+1.22%)

MRNA Moderna
$180.40 /

-3.02 (-1.65%)

MKSI MKS Instruments
$167.71 /

+5.49 (+3.38%)

LLNW Limelight Networks
$3.58 /

-0.98 (-21.49%)

LITE Lumentum
$94.62 /

+2.03 (+2.19%)

IMGN ImmunoGen
$10.56 /

+2.455 (+30.29%)

IIVI II-VI
$93.24 /

-6.39 (-6.41%)

HUBS HubSpot
$503.52 /

+71.28 (+16.49%)

FOLD Amicus
$12.73 /

-6.03 (-32.14%)

EXPE Expedia
$146.81 /

-2.81 (-1.88%)

DIS Disney
$189.57 /

-1.39 (-0.73%)

COHR Coherent
$259.58 /

+33.35 (+14.74%)

XERS Xeris Pharmaceuticals
$7.08 /

+0.46 (+6.95%)

08/20/20 Mizuho
Mizuho sees no material impact to Xeris following FDA letter about advertising
04/23/20 Mizuho
Xeris Pharmaceuticals price target lowered to $14 from $18 at Mizuho
02/20/20 Mizuho
Xeris Pharmaceuticals price target lowered to $18 from $22 at Mizuho
02/18/20
Fly Intel: Top five analyst initiations
DIS Disney
$189.57 /

-1.39 (-0.73%)

02/12/21 Loop Capital
Disney price target raised to $230 from $190 at Loop Capital
02/12/21 Evercore ISI
Disney price target raised to $210 from $200 at Evercore ISI
02/12/21 JPMorgan
Disney price target raised to $220 from $210 at JPMorgan
02/12/21 Credit Suisse
Disney price target raised to $218 from $192 at Credit Suisse
EXPE Expedia
$146.81 /

-2.81 (-1.88%)

02/12/21 Stifel
Expedia price target raised to $140 from $117 at Stifel
02/12/21 Cowen
Expedia price target raised to $150 from $140 at Cowen
02/12/21 Benchmark
Expedia price target raised to $175 from $120 at Benchmark
02/12/21 Barclays
Expedia price target raised to $167 from $140 at Barclays
IIVI II-VI
$93.24 /

-6.39 (-6.41%)

02/12/21 Benchmark
Benchmark maintains Buy rating on II-VI after Coherent bid
02/10/21 DA Davidson
II-VI price target raised to $115 from $60 at DA Davidson
02/10/21 Cowen
II-VI price target raised to $124 from $86 at Cowen
02/10/21 Canaccord
II-VI price target raised to $152 from $86 at Canaccord
COHR Coherent
$259.58 /

+33.35 (+14.74%)

02/11/21 Benchmark
Coherent downgraded to Hold from Buy at Benchmark
02/08/21 Stifel
Coherent bid may force Lumentum to raise offer, says Stifel
02/08/21 Benchmark
Coherent deal with MKS could face regulators' scrutiny, says Benchmark
LITE Lumentum
$94.62 /

+2.03 (+2.19%)

MKSI MKS Instruments
$167.71 /

+5.49 (+3.38%)

MRNA Moderna
$180.40 /

-3.02 (-1.65%)

02/03/21 Piper Sandler
Moderna's vaccine approved in Singapore, says Piper Sandler
02/01/21
Fly Intel: Top five analyst downgrades
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Oppenheimer
Moderna price target raised to $206 from $178 at Oppenheimer
PFE Pfizer
$34.85 /

+0.42 (+1.22%)

02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
02/03/21 Mizuho
Pfizer price target lowered to $42 from $44 at Mizuho
IMGN ImmunoGen
$10.56 /

+2.455 (+30.29%)

12/07/20 Piper Sandler
ImmunoGen price target raised to $6.50 from $5.50 at Piper Sandler
10/26/20 H.C. Wainwright
ImmunoGen assumed with a Buy at H.C. Wainwright
10/19/20 Piper Sandler
Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler
10/05/20 Piper Sandler
Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question'
HUBS HubSpot
$503.52 /

+71.28 (+16.49%)

02/12/21 Needham
HubSpot price target raised to $520 from $400 at Needham
02/12/21 Cowen
HubSpot price target raised to $510 from $400 at Cowen
02/12/21 Raymond James
HubSpot upgraded to Strong Buy from Outperform at Raymond James
02/12/21 Truist
HubSpot price target raised to $600 from $455 at Truist
FOLD Amicus
$12.73 /

-6.03 (-32.14%)

02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 JPMorgan
Amicus downgraded to Neutral on Pompe disease miss at JPMorgan
02/12/21 SVB Leerink
Amicus downgraded to Market Perform from Outperform at SVB Leerink
02/12/21 Cantor Fitzgerald
Amicus downgraded to Neutral from Overweight at Cantor Fitzgerald
LLNW Limelight Networks
$3.58 /

-0.98 (-21.49%)

02/12/21 Lake Street
Limelight Networks price target lowered to $6 from $9 at Lake Street
02/12/21 DA Davidson
Limelight Networks downgraded to Underperform from Neutral at DA Davidson
02/12/21 Raymond James
Limelight Networks downgraded to Market Perform from Outperform at Raymond James
02/12/21 Truist
Limelight Networks downgraded to Hold from Buy at Truist
NWL Newell Brands
$24.15 /

-1.89 (-7.26%)

02/04/21 Deutsche Bank
Newell Brands price target raised to $23 from $18 at Deutsche Bank
01/08/21 BofA
Newell Brands upgraded to Buy on shift away from home at BofA
01/08/21 BofA
Newell Brands upgraded to Buy from Neutral at BofA
01/04/21 Jefferies
Jefferies upgrades 'underappreciated' Newell Brands to Buy from Hold
XERS Xeris Pharmaceuticals
$7.08 /

+0.46 (+6.95%)

PFE Pfizer
$34.85 /

+0.42 (+1.22%)

NWL Newell Brands
$24.15 /

-1.89 (-7.26%)

MRNA Moderna
$180.40 /

-3.02 (-1.65%)

MKSI MKS Instruments
$167.71 /

+5.49 (+3.38%)

LLNW Limelight Networks
$3.58 /

-0.98 (-21.49%)

LITE Lumentum
$94.62 /

+2.03 (+2.19%)

IMGN ImmunoGen
$10.56 /

+2.455 (+30.29%)

IIVI II-VI
$93.24 /

-6.39 (-6.41%)

HUBS HubSpot
$503.52 /

+71.28 (+16.49%)

FOLD Amicus
$12.73 /

-6.03 (-32.14%)

EXPE Expedia
$146.81 /

-2.81 (-1.88%)

DIS Disney
$189.57 /

-1.39 (-0.73%)

COHR Coherent
$259.58 /

+33.35 (+14.74%)

  • 02
    Jul
  • 26
    Jun
  • 19
    May
PFE Pfizer
$34.85 /

+0.42 (+1.22%)

MRNA Moderna
$180.40 /

-3.02 (-1.65%)

IIVI II-VI
$93.24 /

-6.39 (-6.41%)

HUBS HubSpot
$503.52 /

+71.28 (+16.49%)

FOLD Amicus
$12.73 /

-6.03 (-32.14%)

EXPE Expedia
$146.81 /

-2.81 (-1.88%)

DIS Disney
$189.57 /

-1.39 (-0.73%)

COHR Coherent
$259.58 /

+33.35 (+14.74%)

XERS Xeris Pharmaceuticals
$7.08 /

+0.46 (+6.95%)

PFE Pfizer
$34.85 /

+0.42 (+1.22%)

NWL Newell Brands
$24.15 /

-1.89 (-7.26%)

MRNA Moderna
$180.40 /

-3.02 (-1.65%)

MKSI MKS Instruments
$167.71 /

+5.49 (+3.38%)

LLNW Limelight Networks
$3.58 /

-0.98 (-21.49%)

LITE Lumentum
$94.62 /

+2.03 (+2.19%)

IMGN ImmunoGen
$10.56 /

+2.455 (+30.29%)

IIVI II-VI
$93.24 /

-6.39 (-6.41%)

HUBS HubSpot
$503.52 /

+71.28 (+16.49%)

FOLD Amicus
$12.73 /

-6.03 (-32.14%)

EXPE Expedia
$146.81 /

-2.81 (-1.88%)

DIS Disney
$189.57 /

-1.39 (-0.73%)

COHR Coherent
$259.58 /

+33.35 (+14.74%)

XERS Xeris Pharmaceuticals
$7.08 /

+0.46 (+6.95%)

PFE Pfizer
$34.85 /

+0.42 (+1.22%)

NWL Newell Brands
$24.15 /

-1.89 (-7.26%)

MRNA Moderna
$180.40 /

-3.02 (-1.65%)

LLNW Limelight Networks
$3.58 /

-0.98 (-21.49%)

LITE Lumentum
$94.62 /

+2.03 (+2.19%)

FOLD Amicus
$12.73 /

-6.03 (-32.14%)

EXPE Expedia
$146.81 /

-2.81 (-1.88%)

DIS Disney
$189.57 /

-1.39 (-0.73%)

Hot Stocks
Coherent confirms receipt of unsolicited proposal from II-VI » 11:03
02/12/21
02/12
11:03
02/12/21
11:03
COHR

Coherent

$260.90 /

+34.67 (+15.33%)

, IIVI

II-VI

$96.13 /

-3.5 (-3.51%)

, LITE

Lumentum

$95.50 /

+2.91 (+3.14%)

, MKSI

MKS Instruments

$170.35 /

+8.13 (+5.01%)

Coherent (COHR) announced…

Coherent (COHR) announced that it has received an unsolicited acquisition proposal from II-VI Incorporated (IIVI) to acquire Coherent in a cash and stock transaction. Under the terms of II-VI's proposal, each share of Coherent common stock would be exchanged for $130.00 in cash and 1.3055 shares of II-VI common stock at the completion of the transaction. On January 19, 2021, Coherent announced that it had entered into a merger agreement with Lumentum Holdings (LITE), pursuant to which Lumentum agreed to acquire Coherent and each share of Coherent common stock would be exchanged for $100.00 in cash and 1.1851 shares of Lumentum common stock at the completion of the transaction. On February 8, 2021, Coherent announced that it had received an unsolicited acquisition proposal from MKS Instruments (MKSI). Under the terms of MKS' proposal, each share of Coherent common stock would be exchanged for $115.00 in cash and 0.7473 of a share of MKS common stock at the completion of the transaction. The pending transaction with Lumentum and proposed transactions with MKS and II-VI would all be subject to customary closing conditions, including receipt of U.S. and foreign antitrust approvals and stockholder approvals. Coherent's board of directors, consistent with its fiduciary duties and in consultation with its financial and legal advisors, is carefully reviewing and considering II-VI's proposal. There can be no assurances that Coherent will conclude that the transaction proposed by II-VI is superior to Coherent's pending transaction with Lumentum or the proposal from MKS. Coherent stockholders are advised to take no action at this time and encouraged to await a final determination from Coherent's board of directors. Notwithstanding its receipt of MKS' proposal and II-VI's proposal, Coherent's board of directors continues to recommend Coherent's merger agreement with Lumentum to its stockholders. Coherent's board of directors is not modifying or withdrawing its recommendation with respect to the Lumentum merger agreement and the Lumentum merger at this time, or proposing to do so, and is not making any recommendation with respect to MKS' proposal or II-VI's proposal at this time.

ShowHide Related Items >><<
MKSI MKS Instruments
$170.35 /

+8.13 (+5.01%)

LITE Lumentum
$95.50 /

+2.91 (+3.14%)

IIVI II-VI
$96.13 /

-3.5 (-3.51%)

COHR Coherent
$260.90 /

+34.67 (+15.33%)

COHR Coherent
$260.90 /

+34.67 (+15.33%)

02/12/21 Benchmark
Benchmark maintains Buy rating on II-VI after Coherent bid
02/11/21 Benchmark
Coherent downgraded to Hold from Buy at Benchmark
02/08/21 Stifel
Coherent bid may force Lumentum to raise offer, says Stifel
02/08/21 Benchmark
Coherent deal with MKS could face regulators' scrutiny, says Benchmark
IIVI II-VI
$96.13 /

-3.5 (-3.51%)

02/10/21 DA Davidson
II-VI price target raised to $115 from $60 at DA Davidson
02/10/21 Cowen
II-VI price target raised to $124 from $86 at Cowen
02/10/21 Canaccord
II-VI price target raised to $152 from $86 at Canaccord
LITE Lumentum
$95.50 /

+2.91 (+3.14%)

MKSI MKS Instruments
$170.35 /

+8.13 (+5.01%)

MKSI MKS Instruments
$170.35 /

+8.13 (+5.01%)

LITE Lumentum
$95.50 /

+2.91 (+3.14%)

IIVI II-VI
$96.13 /

-3.5 (-3.51%)

COHR Coherent
$260.90 /

+34.67 (+15.33%)

  • 02
    Jul
IIVI II-VI
$96.13 /

-3.5 (-3.51%)

COHR Coherent
$260.90 /

+34.67 (+15.33%)

MKSI MKS Instruments
$170.35 /

+8.13 (+5.01%)

LITE Lumentum
$95.50 /

+2.91 (+3.14%)

IIVI II-VI
$96.13 /

-3.5 (-3.51%)

COHR Coherent
$260.90 /

+34.67 (+15.33%)

LITE Lumentum
$95.50 /

+2.91 (+3.14%)

Recommendations
Benchmark maintains Buy rating on II-VI after Coherent bid » 10:05
02/12/21
02/12
10:05
02/12/21
10:05
IIVI

II-VI

$95.20 /

-4.435 (-4.45%)

, COHR

Coherent

$259.94 /

+33.71 (+14.90%)

, LITE

Lumentum

$95.81 /

+3.22 (+3.48%)

, MKSI

MKS Instruments

$168.50 /

+6.28 (+3.87%)

Benchmark analyst Mark…

Benchmark analyst Mark Miller maintains a Buy rating with a $105 price target on II-VI (IIVI) after the company announced this morning a bid of about $6.5B for Coherent (COHR) estimated to be worth $260 per share in cash and stock. The combination should offer growth and increased scale for II-VI with a greater footprint in Korea and China and it would expands the company's presence in the aerospace and life sciences segments, said Miller, who added that II-VI has experience in successfully managing acquisitions of diverse firms and "knows the regulatory situation in China." Similar to Lumentum's (LITE) offer, he believes a deal with II-VI would be complementary and not have some of the market overlaps, such as in picosecond and femtosecond lasers, that MKS Instruments (MKSI) has, Miller added.

ShowHide Related Items >><<
MKSI MKS Instruments
$168.50 /

+6.28 (+3.87%)

LITE Lumentum
$95.81 /

+3.22 (+3.48%)

IIVI II-VI
$95.20 /

-4.435 (-4.45%)

COHR Coherent
$259.94 /

+33.71 (+14.90%)

IIVI II-VI
$95.20 /

-4.435 (-4.45%)

02/10/21 DA Davidson
II-VI price target raised to $115 from $60 at DA Davidson
02/10/21 Cowen
II-VI price target raised to $124 from $86 at Cowen
02/10/21 Canaccord
II-VI price target raised to $152 from $86 at Canaccord
02/10/21 Citi
II-VI price target raised to $115 from $110 at Citi
COHR Coherent
$259.94 /

+33.71 (+14.90%)

02/11/21 Benchmark
Coherent downgraded to Hold from Buy at Benchmark
02/08/21 Stifel
Coherent bid may force Lumentum to raise offer, says Stifel
02/08/21 Benchmark
Coherent deal with MKS could face regulators' scrutiny, says Benchmark
02/02/21 Stifel
Stifel adds Fabrinet to Select List, ups target to $94 from $82
LITE Lumentum
$95.81 /

+3.22 (+3.48%)

02/03/21 B. Riley Securities
Lumentum shares oversold after 19% pullback, says B. Riley Securities
MKSI MKS Instruments
$168.50 /

+6.28 (+3.87%)

01/29/21 Citi
MKS Instruments price target lowered to $180 from $200 at Citi
MKSI MKS Instruments
$168.50 /

+6.28 (+3.87%)

LITE Lumentum
$95.81 /

+3.22 (+3.48%)

IIVI II-VI
$95.20 /

-4.435 (-4.45%)

COHR Coherent
$259.94 /

+33.71 (+14.90%)

  • 02
    Jul
IIVI II-VI
$95.20 /

-4.435 (-4.45%)

COHR Coherent
$259.94 /

+33.71 (+14.90%)

MKSI MKS Instruments
$168.50 /

+6.28 (+3.87%)

LITE Lumentum
$95.81 /

+3.22 (+3.48%)

IIVI II-VI
$95.20 /

-4.435 (-4.45%)

COHR Coherent
$259.94 /

+33.71 (+14.90%)

LITE Lumentum
$95.81 /

+3.22 (+3.48%)

Hot Stocks
II-VI offers to acquire Coherent for $260 per share » 08:03
02/12/21
02/12
08:03
02/12/21
08:03
IIVI

II-VI

$99.61 /

+5.31 (+5.63%)

, COHR

Coherent

$226.90 /

+5.3998 (+2.44%)

, LITE

Lumentum

$92.59 /

+3.8 (+4.28%)

II-VI Incorporated…

II-VI Incorporated (IIVI), a global leader in engineered materials and optoelectronic components, today announced it has made an offer to acquire Coherent (COHR) in a cash and stock transaction. Under the terms of II-VI's proposal made in a letter to Coherent's Board of Directors, Coherent's shareholders would receive $130.00 in cash and 1.3055 II-VI common shares for each Coherent share. Based on yesterday's closing price of II-VI shares, II-VI's proposal is valued at $260.00 per Coherent share. II-VI's proposal represents a premium of 24.0% to the implied value of Coherent's merger agreement with Lumentum (LITE), based on Lumentum's closing share price yesterday, and a 9.8% premium to the implied value of MKS Instruments' acquisition proposal based on MKS' closing share price yesterday. Moreover, since II-VI has substantially less product overlap with Coherent than either Lumentum or MKS, II-VI believes there is greater certainty of closing and with less potential impact to the combined value. II-VI also expects to achieve estimated, combined run-rate synergies of $200 million annually within 36 months. II-VI anticipates the transaction to be accretive to non-GAAP EPS in the second year following closing. II-VI intends to fund the transaction with cash on hand and debt financing led by J.P. Morgan Securities LLC. In addition, Bain Capital has expressed strong interest in a potential equity investment in the combined company. The execution of a definitive merger agreement between Coherent and II-VI would be subject to approval by each company's Board of Directors and completion of the transaction would be subject to customary closing conditions, including receipt of required regulatory approvals and approval of II-VI and Coherent shareholders.

ShowHide Related Items >><<
LITE Lumentum
$92.59 /

+3.8 (+4.28%)

IIVI II-VI
$99.61 /

+5.31 (+5.63%)

COHR Coherent
$226.90 /

+5.3998 (+2.44%)

IIVI II-VI
$99.61 /

+5.31 (+5.63%)

02/10/21 DA Davidson
II-VI price target raised to $115 from $60 at DA Davidson
02/10/21 Cowen
II-VI price target raised to $124 from $86 at Cowen
02/10/21 Canaccord
II-VI price target raised to $152 from $86 at Canaccord
02/10/21 Citi
II-VI price target raised to $115 from $110 at Citi
COHR Coherent
$226.90 /

+5.3998 (+2.44%)

02/11/21 Benchmark
Coherent downgraded to Hold from Buy at Benchmark
02/08/21 Stifel
Coherent bid may force Lumentum to raise offer, says Stifel
02/08/21 Benchmark
Coherent deal with MKS could face regulators' scrutiny, says Benchmark
02/02/21 Stifel
Stifel adds Fabrinet to Select List, ups target to $94 from $82
LITE Lumentum
$92.59 /

+3.8 (+4.28%)

02/03/21 B. Riley Securities
Lumentum shares oversold after 19% pullback, says B. Riley Securities
LITE Lumentum
$92.59 /

+3.8 (+4.28%)

IIVI II-VI
$99.61 /

+5.31 (+5.63%)

COHR Coherent
$226.90 /

+5.3998 (+2.44%)

  • 02
    Jul
IIVI II-VI
$99.61 /

+5.31 (+5.63%)

COHR Coherent
$226.90 /

+5.3998 (+2.44%)

LITE Lumentum
$92.59 /

+3.8 (+4.28%)

IIVI II-VI
$99.61 /

+5.31 (+5.63%)

COHR Coherent
$226.90 /

+5.3998 (+2.44%)

LITE Lumentum
$92.59 /

+3.8 (+4.28%)

Hot Stocks
II-VI offers to acquire Coherent for $260 per share  08:02
02/12/21
02/12
08:02
02/12/21
08:02
IIVI

II-VI

$99.61 /

+5.31 (+5.63%)

, COHR

Coherent

$226.90 /

+5.3998 (+2.44%)

 
ShowHide Related Items >><<
IIVI II-VI
$99.61 /

+5.31 (+5.63%)

COHR Coherent
$226.90 /

+5.3998 (+2.44%)

IIVI II-VI
$99.61 /

+5.31 (+5.63%)

02/10/21 DA Davidson
II-VI price target raised to $115 from $60 at DA Davidson
02/10/21 Cowen
II-VI price target raised to $124 from $86 at Cowen
02/10/21 Canaccord
II-VI price target raised to $152 from $86 at Canaccord
02/10/21 Citi
II-VI price target raised to $115 from $110 at Citi
COHR Coherent
$226.90 /

+5.3998 (+2.44%)

02/11/21 Benchmark
Coherent downgraded to Hold from Buy at Benchmark
02/08/21 Stifel
Coherent bid may force Lumentum to raise offer, says Stifel
02/08/21 Benchmark
Coherent deal with MKS could face regulators' scrutiny, says Benchmark
02/02/21 Stifel
Stifel adds Fabrinet to Select List, ups target to $94 from $82
IIVI II-VI
$99.61 /

+5.31 (+5.63%)

COHR Coherent
$226.90 /

+5.3998 (+2.44%)

  • 02
    Jul
IIVI II-VI
$99.61 /

+5.31 (+5.63%)

COHR Coherent
$226.90 /

+5.3998 (+2.44%)

IIVI II-VI
$99.61 /

+5.31 (+5.63%)

COHR Coherent
$226.90 /

+5.3998 (+2.44%)

Hot Stocks
Coherent trading halted, news dissemination  08:00
02/12/21
02/12
08:00
02/12/21
08:00
COHR

Coherent

$226.90 /

+5.3998 (+2.44%)

 
ShowHide Related Items >><<
COHR Coherent
$226.90 /

+5.3998 (+2.44%)

COHR Coherent
$226.90 /

+5.3998 (+2.44%)

02/11/21 Benchmark
Coherent downgraded to Hold from Buy at Benchmark
02/08/21 Stifel
Coherent bid may force Lumentum to raise offer, says Stifel
02/08/21 Benchmark
Coherent deal with MKS could face regulators' scrutiny, says Benchmark
02/02/21 Stifel
Stifel adds Fabrinet to Select List, ups target to $94 from $82
COHR Coherent
$226.90 /

+5.3998 (+2.44%)

COHR Coherent
$226.90 /

+5.3998 (+2.44%)

COHR Coherent
$226.90 /

+5.3998 (+2.44%)

Periodicals
II-VI plans to bid $260 a share for Coherent, WSJ reports » 07:22
02/12/21
02/12
07:22
02/12/21
07:22
IIVI

II-VI

$99.61 /

+5.31 (+5.63%)

, COHR

Coherent

$226.90 /

+5.3998 (+2.44%)

, LITE

Lumentum

$92.59 /

+3.8 (+4.28%)

, MKSI

MKS Instruments

$162.67 /

+10.78 (+7.10%)

II-VI (IIVI) plans to bid…

II-VI (IIVI) plans to bid $260 a share, or about $6.5B, for Coherent (COHR) as soon as Friday, The Wall Street Journal's Cara Lombardo reports, citing people familiar with the matter. According to the people, II-VI plans to offer $130 a share in cash and the rest in shares. Coherent already agreed to sell itself to Lumentum (LITE) for about $226 a share, while MKS Instruments (MKSI) last week made an offer of roughly $240 a share. Reference Link

ShowHide Related Items >><<
LITE Lumentum
$92.59 /

+3.8 (+4.28%)

IIVI II-VI
$99.61 /

+5.31 (+5.63%)

COHR Coherent
$226.90 /

+5.3998 (+2.44%)

IIVI II-VI
$99.61 /

+5.31 (+5.63%)

02/10/21 DA Davidson
II-VI price target raised to $115 from $60 at DA Davidson
02/10/21 Cowen
II-VI price target raised to $124 from $86 at Cowen
02/10/21 Canaccord
II-VI price target raised to $152 from $86 at Canaccord
02/10/21 Citi
II-VI price target raised to $115 from $110 at Citi
COHR Coherent
$226.90 /

+5.3998 (+2.44%)

02/11/21 Benchmark
Coherent downgraded to Hold from Buy at Benchmark
02/08/21 Stifel
Coherent bid may force Lumentum to raise offer, says Stifel
02/08/21 Benchmark
Coherent deal with MKS could face regulators' scrutiny, says Benchmark
02/02/21 Stifel
Stifel adds Fabrinet to Select List, ups target to $94 from $82
LITE Lumentum
$92.59 /

+3.8 (+4.28%)

02/03/21 B. Riley Securities
Lumentum shares oversold after 19% pullback, says B. Riley Securities
MKSI MKS Instruments
$162.67 /

+10.78 (+7.10%)

01/29/21 Citi
MKS Instruments price target lowered to $180 from $200 at Citi
MKSI MKS Instruments
$162.67 /

+10.78 (+7.10%)

LITE Lumentum
$92.59 /

+3.8 (+4.28%)

IIVI II-VI
$99.61 /

+5.31 (+5.63%)

COHR Coherent
$226.90 /

+5.3998 (+2.44%)

  • 02
    Jul
IIVI II-VI
$99.61 /

+5.31 (+5.63%)

COHR Coherent
$226.90 /

+5.3998 (+2.44%)

MKSI MKS Instruments
$162.67 /

+10.78 (+7.10%)

LITE Lumentum
$92.59 /

+3.8 (+4.28%)

IIVI II-VI
$99.61 /

+5.31 (+5.63%)

COHR Coherent
$226.90 /

+5.3998 (+2.44%)

LITE Lumentum
$92.59 /

+3.8 (+4.28%)

Options
Lumentum call volume above normal and directionally bullish » 15:25
02/11/21
02/11
15:25
02/11/21
15:25
LITE

Lumentum

$93.00 /

+4.21 (+4.74%)

Bullish option flow…

Bullish option flow detected in Lumentum with 12,630 calls trading, 3x expected, and implied vol increasing over 1 point to 46.46%. 2/12 weekly 91 calls and Feb-21 95 calls are the most active options, with total volume in those strikes near 5,900 contracts. The Put/Call Ratio is 0.09. Earnings are expected on May 4th.

ShowHide Related Items >><<
LITE Lumentum
$93.00 /

+4.21 (+4.74%)

LITE Lumentum
$93.00 /

+4.21 (+4.74%)

02/11/21 Benchmark
Coherent downgraded to Hold from Buy at Benchmark
02/08/21 Stifel
Coherent bid may force Lumentum to raise offer, says Stifel
02/08/21 Benchmark
Coherent deal with MKS could face regulators' scrutiny, says Benchmark
02/03/21 B. Riley Securities
Lumentum shares oversold after 19% pullback, says B. Riley Securities
LITE Lumentum
$93.00 /

+4.21 (+4.74%)

LITE Lumentum
$93.00 /

+4.21 (+4.74%)

LITE Lumentum
$93.00 /

+4.21 (+4.74%)

LITE Lumentum
$93.00 /

+4.21 (+4.74%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.